PT  - JOURNAL ARTICLE
AU  - Kierkegaard, Patrick
AU  - Hicks, Timothy
AU  - Yang, Yaling
AU  - Lee, Joseph
AU  - Hayward, Gail
AU  - Turner, Philip J.
AU  - Allen, A. Joy
AU  - Nicholson, Brian D.
TI  - Primary care and point-of-care testing during a pandemic: Clinician’s perspectives on integrating rapid testing for COVID-19 into the primary care pathway
AID  - 10.1101/2021.04.13.21255347
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.13.21255347
4099  - http://medrxiv.org/content/early/2021/04/19/2021.04.13.21255347.short
4100  - http://medrxiv.org/content/early/2021/04/19/2021.04.13.21255347.full
AB  - Background Real-world evidence to support the adoption of SARS-CoV-2 point-of-care (POC) tests in primary care is limited. As the first point of contact of the health system for most patients, POC testing can potentially support general practitioners (GPs) quickly identify infectious and non-infectious individuals to rapidly inform patient triaging, clinical management, and safely restore more in-person services.Objectives To explore the potential role of SARS-CoV-2 point-of-care testing in primary care services.Design A qualitative study using an inductive thematic analysis.Setting 21 general practices located across three regions in England.Results Three major themes were identified related to POC test implementation in primary care: (1) Insights into SARS-CoV-2 POC tests; (2) System and organisational factors; and (3) Practice-level service delivery strategies. Thematic subcategories included involvement in rapid testing, knowledge and perception of the current POC testing landscape, capacity for testing, economic concerns, resource necessities, perception of personal risk and safety, responsibility for administering the test, and targeted testing strategies.Conclusion GPs knowledge of POC tests influences their degree of trust, uncertainty, and their perception of risk of POC test use. Concerns around funding, occupational exposure, and workload play a crucial role in GPs hesitation to provide POC testing services. These concerns could potentially be addressed with government funding, the use of targeted testing, and improved triaging strategies to limit testing to essential patient cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), which is funded by UK Research and Innovation, the Department of Health and Social Care through the National Institute for Health Research, Asthma UK and the British Lung Foundation. PK is supported by the National Institute for Health Research (NIHR) London In Vitro Diagnostics Co-operative at Imperial College Healthcare NHS Trust. TH and AJA are supported by the NIHR Newcastle In Vitro Diagnostics Co-operative at Newcastle upon Tyne Hospitals NHS Foundation Trust. YY, BN, PJT, GH, and JL are supported by the National Institute for Health Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Imperial College London, University of Oxford, or Newcastle University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved and registered as a service evaluation by the Newcastle Joint Research Office and recorded on the Newcastle upon Tyne Hospital Foundation Trust's Clinical Effectiveness Register (Project no. 10222). The Newcastle University Faculty of Medical Sciences Research Ethics Committee reviewed the protocol and deemed the work exempt from ethical approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its supporting information files.(BMA)British Medical Association(CCG)Clinical commissioning group(COVID-19)Coronavirus Disease 2019(GP)General Practitioner(HCA)Health care assistant(LCRN)Local Clinical Research Network(LMC)Local Medical Committees(NIHR)National Institute of Health Research(POC)Point of care(QOF)Quality and Outcomes Framework(SARS-CoV-2)Severe acute respiratory syndrome coronavirus 2